GMED
Globus Medical, Inc.
NYSE · Healthcare · Medical - Devices · US
$75.65
−1.38%Year over year
Reported trailing growth
- Revenue
- +19.7%
- EBITDA
- +52.8%
- EBIT
- +131.9%
- EPS
- +51.5%
- Free cash flow
- +45.1%
- Operating cash flow
- +36.0%
Forward estimates
Based on analyst estimates
- Revenue
- +6.1%
- EBITDA
- +21.5%
- EPS
- +32.0%
Three-year CAGR
- Revenue
- +42.2%
- EBITDA
- +42.8%
- EBIT
- +28.2%
- Net income
- +41.4%
- EPS
- +28.2%
- Free cash flow
- +78.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026